Carisma Therapeutics
Financing Round
- Series B
Round Led by Symbiosis
Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.
View Website
Modality
- Cell Therapy
Indications
- Immunology
- Neurology
- Oncology
Development Status
- Phase 1